Benzinga | Sep 21, 2021 04:57AM EDT

Oppenheimer Initiates Coverage On Portage Biotech with Outperform Rating, Announces Price Target of $30

Oppenheimer analyst Kevin DeGeeter initiates coverage on Portage Biotech (NASDAQ:PRTG) with a Outperform rating and announces Price Target of $30.